Market revenue in 2020 | USD 109.8 million |
Market revenue in 2028 | USD 264.1 million |
Growth rate | 11.6% (CAGR from 2020 to 2028) |
Largest segment | Laboratory technologies |
Fastest growing segment | Online Technologies |
Historical data | 2020 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Laboratory Technologies, Online Technologies |
Key market players worldwide | Thermo Fisher Scientific Inc, Pfizer Inc, Sartorius AG, Stemcell Holdings Inc Ordinary Shares, Illumina Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Merck KGaA, Qiagen NV, Shimadzu Corp, Eurofins Scientific SE, Charles River Laboratories International Inc, Takara Bio Inc, Olympus Corp, Avantor Inc, Aurora Innovation Inc Class A, Standard BioTools Inc, Celerion, Cole-Parmer, Hartford Schroders International Stk I, Revvity Inc, Fluidigm Corporation, Polyplus-transfection, Hamilton Lane Inc Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to covid-19 vaccine development tools market will help companies and investors design strategic landscapes.
Laboratory technologies was the largest segment with a revenue share of 95.36% in 2020. Horizon Databook has segmented the Spain covid-19 vaccine development tools market based on laboratory technologies, online technologies covering the revenue growth of each sub-segment from 2020 to 2028.
In 2021, Spain held the smallest share of revenue in COVID-19 vaccine development tools market in Europe. The market was supported by various nonprofit organizations and local players in the region. For instance, in April 2020, Club De Madrid contributed USD 209,369 to Spain’s National Biotechnology Center for developing COVID-19 vaccine.
It is a public research institution that applies genetic engineering techniques to understand the ongoing pandemic. The institution has significant experience in developing vaccine candidates against Zika and Ebola. Similarly, in August 2021, a Spain based company, Hipra received approval for initial round of clinical trials for COVID-19 vaccine.
The company applied the same mRNA technology in the vaccine as Pfizer and Moderns. Hipra has anticipated producing around 400 million doses in 2022 and is expected to scale up to 1.2 billion in 2023. The other significant player was Promega Biotech Iberic, which made a considerable contribution to the COVID-19 response in Spain.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain covid-19 vaccine development tools market , including forecasts for subscribers. This country databook contains high-level insights into Spain covid-19 vaccine development tools market from 2020 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account